CASI 1.85 ▲ 5.71% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    CASI Pharmaceuticals Inc.

    NASDAQ: CASI · Real-Time Price · USD
    1.85
    0.10 (5.71%)
    At close: Oct 03, 2025, 3:59 PM
    1.90
    2.68%
    After-hours: Oct 03, 2025, 06:52 PM EDT
    5.71%
    Bid 1.83
    Market Cap 28.66M
    Revenue (ttm) 31.56M
    Net Income (ttm) -46.89M
    EPS (ttm) -2.89
    PE Ratio (ttm) -0.64
    Forward PE -1.21
    Analyst Buy
    Dividends n/a
    Ask 1.99
    Volume 187,381
    Avg. Volume (20D) 1,305,241
    Open 1.85
    Previous Close 1.75
    Day's Range 1.81 - 2.04
    52-Week Range 1.09 - 7.50
    Beta 0.64
    Ex-Dividend Date n/a

    About CASI

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol CASI
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for CASI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts
    2 months ago
    +51.16%
    CASI Pharmaceuticals shares are trading higher aft... Unlock content with Pro Subscription
    6 months ago
    +0.95%
    CASI Pharmaceuticals shares are trading higher after the company received a $20 million proposal from CEO Dr. Wei-Wu He to acquire its business operations in China.
    news image

    1 week ago · accessnewswire.com

    CASI Pharmaceuticals Appoints James Huang to Board of Directors

    - Industry veteran brings over 35 years of biotech experience as a successful entrepreneur and investor - Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb) S...

    news image

    4 weeks ago · accessnewswire.com

    CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

    - CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody - Safety profile observed in first four dose cohorts supports continued development - No serious adverse events or ...

    news image

    1 month ago · accessnewswire.com

    CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

    SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for pati...

    news image

    1 month ago · accessnewswire.com

    CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

    - Industry veteran brings extensive senior level leadership and expertise in biologics development, strategic partnerships, mergers and acquisitions across biotech and large pharma organizations - Ope...

    news image

    1 month ago · accessnewswire.com

    CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

    SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 29, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies fo...

    news image

    1 month ago · accessnewswire.com

    CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

    SAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients wit...

    news image

    2 months ago · accessnewswire.com

    CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)

    CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope Phase 1 study in adults with active and chronic active renal allograft AMR planned to initiate AMR is ...

    news image

    2 months ago · accessnewswire.com

    CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

    -- David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record o...

    Add to Watchlist